Study of Efficacy & Safety of Oral YM087 in Subjects With Euvolemic or Hypervolemic Hyponatremia
A 5-Day, Double-Blind, Placebo-Controlled Multicenter Study of Oral YM087 (CI-1025) to Assess Efficacy and Safety in Patients With Euvolemic or Hypervolemic Hyponatremia
Sponsor: Cumberland Pharmaceuticals
A PHASE3 clinical study on Hyponatremia, this trial is completed. The trial is conducted by Cumberland Pharmaceuticals and has accumulated 6 data snapshots since 2000. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Jan 2000
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cumberland Pharmaceuticals
- Parke-Davis
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bad Nauheim, Germany, Barcelona, Spain, Berlin, Germany, Brussels, Belgium, Cardiff, United Kingdom, Córdoba, Spain, Delft, Netherlands, Dresdan, Germany, Ferrara, Italy, Garches, France and 19 more location s